Bliss GVS Pharma Ltd - Stock Valuation and Financial Performance

BSE: 506197 | NSE: BLISSGVS | Pharmaceuticals & Drugs | Small Cap

Bliss GVS Pharma Share Price

112.20 -1.95 -1.71%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Bliss GVS Pharma

Overall Rating
Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Bliss GVS Pharma stock performance -

mw4me loader
P/E Ratio (SA):
17.52
Market Cap:
1,195.1 Cr.
52-wk low:
69.2
52-wk high:
149

Is Bliss GVS Pharma Ltd an attractive stock to invest in?

1. Is Bliss GVS Pharma Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Bliss GVS Pharma Ltd is a below average quality company.

2. Is Bliss GVS Pharma Ltd undervalued or overvalued?

The key valuation ratios of Bliss GVS Pharma Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Bliss GVS Pharma Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bliss GVS Pharma Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Bliss GVS Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Bliss GVS Pharma Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 12.4%14%13.4%12.2%9.7%8.8%10.6%8.2%9%6.7%-
Value Creation
Index
-0.1-00.0-0.1-0.3-0.4-0.3-0.4-0.4-0.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 288313326348298427442466636598585
Sales YoY Gr.-8.6%4.3%6.6%-14.4%43.2%3.6%5.3%36.7%-6%-
Adj EPS 3.85.15.45.85.25.4767.55.66.5
YoY Gr.-32.9%6.9%6.9%-10.8%4.3%29.6%-13.2%23.3%-24.7%-
BVPS (₹) 30.435.741.947.752.558.566.272.381.289.195.5
Adj Net
Profit
39.252.155.759.553.255.371.862.377.358.468
Cash Flow from Ops. 64.715.459.638.522.748.363.26711443.8-
Debt/CF from Ops. 1.35.91.424.11.51.41.30.81.8-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 8.5%15%10.6%-6%
Adj EPS 4.4%1.7%-6.9%-24.7%
BVPS12.7%11.2%10.4%9.8%
Share Price 9.7% -8.8% 3.4% 57.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
13.715.313.912.910.39.711.28.79.66.57.1
Op. Profit
Mgn %
22.927.629.62929.722.422.719.717.215.115.9
Net Profit
Mgn %
13.616.717.117.117.91316.213.412.19.811.7
Debt to
Equity
0.30.20.20.20.20.10.10.10.10.1-
Working Cap
Days
508497527533621442443471372419215
Cash Conv.
Cycle
144154206206270269307293212233173

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 10.63%

Return on Equity has declined versus last 3 years average to 7.10%

Net Profit has been subdued in last 3 years -6.94%

Sales growth is not so good in last 4 quarters at -0.83%

Latest Financials - Bliss GVS Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 6.5 8.4
TTM Sales (₹ Cr.) 585 757
BVPS (₹.) 95.5 91.7
Reserves (₹ Cr.) 989 950
P/BV 1.20 1.24
PE 17.52 13.59
From the Market
52 Week Low / High (₹) 69.15 / 148.95
All Time Low / High (₹) 0.04 / 230.00
Market Cap (₹ Cr.) 1,195
Equity (₹ Cr.) 10.5
Face Value (₹) 1
Industry PE 47.8

Management X-Ray of Bliss GVS Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Bliss GVS Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales288313326348298427442466636598
Operating Expenses 222227230247209333342374527508
Manufacturing Costs22302766811141817
Material Costs128116114167146225237253344315
Employee Cost 13172225263444596573
Other Costs 5963674931675048100104
Operating Profit 66869710188931009110990
Operating Profit Margin (%) 22.9%27.5%29.6%28.9%29.7%21.8%22.7%19.6%17.2%15.1%
Other Income 3021239113637193351
Interest 9111497376410
Depreciation 4566669141415
Exceptional Items 0000000030
Profit Before Tax 8291100958712012291126116
Tax 28313536304629243430
Profit After Tax 54606659577492689385
PAT Margin (%) 18.7%19.2%20.1%17.0%19.1%17.4%20.9%14.5%14.6%14.3%
Adjusted EPS (₹)5.25.86.45.75.57.29.06.58.98.2
Dividend Payout Ratio (%)10%12%8%10%18%14%6%8%6%6%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 315368432492541603683746841928
Share Capital 10101010101010101010
Reserves 305358422481531593673735831918
Minority Interest0000000000
Debt68596274886771686566
Long Term Debt4530121263136322341
Short Term Debt23285061833736354125
Trade Payables59503564353156678476
Others Liabilities 1627816837293545659070
Total Liabilities 6045556976666947368559461,0801,140

Fixed Assets

Gross Block86120123818393202211270385
Accumulated Depreciation3338446111523374560
Net Fixed Assets548279757278179174224325
CWIP 402204302223
Investments 19192122191919191818
Inventories21232228405561849074
Trade Receivables184211251239283342405349409399
Cash Equivalents 7447578470938712014985
Others Assets248174266216209105105198167236
Total Assets 6045556976666947368559461,0801,140

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 651560382348636711444
PBT 8291100958712012291124116
Adjustment 715728133413541
Changes in Working Capital 9-51-28-47-29-26-30-43-14-76
Tax Paid -33-40-20-37-36-50-32-23-30-38
Cash Flow From Investing Activity -24-21-10-2916-68-60-62-92-13
Capex -9-29-5-3-1-59-67-8-73-94
Net Investments 00-1-32300030
Others -157-3514-97-54-2281
Cash Flow From Financing Activity -50-31-35-15-229-6-12-13-26
Net Proceeds from Shares 0000000022
Net Proceeds from Borrowing 0000024132-5-16
Interest Paid -8-10-11-9-8-3-4-6-2-6
Dividend Paid -5-6-6-5-6-12-12-6-5-5
Others -37-15-180-80-2-2-2-1
Net Cash Flow -9-3714-617-11-3-695
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)18.9317.6216.4112.811.041314.369.4511.689.66
ROCE (%)25.0723.9123.4319.2515.618.817.7512.0214.6812.89
Asset Turnover Ratio0.550.540.520.510.440.60.560.520.630.54
PAT to CFO Conversion(x)1.20.250.910.640.40.650.680.991.230.52
Working Capital Days
Receivable Days253228257255319267308295217246
Inventory Days29252526424048575050
Payable Days2161721361081245467888093

Bliss GVS Pharma Ltd Stock News

Bliss GVS Pharma Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Bliss GVS Pharma on 28-Mar-2024 16:01 is ₹112.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Bliss GVS Pharma stood at ₹1,195.1.
The latest P/E ratio of Bliss GVS Pharma as of 28-Mar-2024 16:01 is 17.52.
The latest P/B ratio of Bliss GVS Pharma as of 28-Mar-2024 16:01 is 1.20.
The 52-week high of Bliss GVS Pharma is ₹148.9 and the 52-week low is ₹69.15.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bliss GVS Pharma is ₹585.1 ( Cr.) .

About Bliss GVS Pharma Ltd

Bliss Gvs Pharma Limited was incorporated on December 11, 1984, as Public Limited Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company has established a foothold in various therapeutic categories including anti-malarial, anti-fungal, contraceptive, laxative, anti-haemorrhoidal, anti-spasmodic, anti-biotic, anti-microbial, antiinflammatory, anti-pyretic, analgesic, and several others.

It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Over the last decade, it has acquired definitive know-how in other dosage forms & therapeutic segments, which is exemplified by its ever-expanding product offering across more than sixty countries. With significant expansion in R & D, Manufacturing & Marketing capabilities, the company is poised for an accelerated rate of growth which makes for very exciting times at Bliss GVS.

Business area of the company

It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company’s most unique product is ‘Today Vaginal Contraceptive’, a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.

Key Milestones

  • 1984: Incorporated as Bliss Chemicals and Pharmaceuticals Limited.
  • 1986: Launch of Flagship product ‘TODAY’, a vaginal contraceptive.
  • 2006: Merger of GVS Labs with Bliss Chemicals & Pharma to form Bliss GVS Pharma Ltd.
  • 2007: Commissioning of manufacturing units for Tablets & Dry Syrups at Palghar.
  • 2010: Commissioning of a state-of-the-artfacility for Suppositories and Pessaries.
  • 2011: EU-GMP approval to the manufacturing facility for suppository facility.
  • 2015: Setting up Healthcare Centres in East Africa under Bliss GVS Healthcare.
  • 2017: Setting up offices in South East Asian countries.
  • 2018: Divestment from Bliss GVS Healthcare.
  • 2019: Setting up of multi-dosage facility (Vevoor Plant).
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.